###### Key question

What is already known about this subject?
=========================================

-   Patients with BRAF V600E metastatic colorectal cancer (mCRC) have an awfully poor prognosis and derive limited benefit from available treatments.

-   Combined targeted strategies against murine sarcoma viral oncogene homolog B (BRAF), Epidermal Growth Factor Receptor (EGFR) and Mitogen-activated protein kinase (MEK)/phosphatidylinositol-3-kinases (PI3K) are under evaluation.

-   Robust preclinical data highlight the potential efficacy of mitotic spindle poisons in this disease subtype.

What does this study adds?
==========================

-   Neither a minimal sign of activity was found with vinorelbine in a cohort of 20 pretreated patients with BRAF V600E mutated mCRC.

-   No Response Evaluation Criteria in Solid Tumour response were reported and only one disease stabilisation lasting more than 2 months was observed.

-   No feasibility or safety concerns were evident.

How might this impact on clinical practice?
===========================================

-   Vinorelbine should not be recommended as a potential option for the treatment of patients with mCRC with BRAF V600E mutated tumours, either in advanced lines.

-   Further investigations on molecular heterogeneity and dynamic evolution of BRAF V600E mutated mCRC are needed.

-   Moving back to the bench is highly recommended before moving to more ambitious and large clinical projects.

Background {#s1}
==========

BRAF V600E mutation is found in about 8% of metastatic colorectal cancer (mCRC) and is an acknowledged marker of poor prognosis, defining a disease subgroup with specific clinical and pathological characteristics.[@R1] Targeted dual/triple combinations achieved promising results in pretreated patients with *BRAF-*mutated mCRC,[@R2] but the possibility to obtain a long-term disease control seems limited by the rapid emergence of acquired resistance.[@R7]

A specific pattern of *BRAF*-like gene signature has been discovered, thus, deepening the knowledge of disease biology and allowing to identify *BRAF* wild-type tumours with a similar aggressive clinical behaviour.[@R9] A recent work looked for specific vulnerability genes whose suppression could interfere with cancer progression in *BRAF*-like models.[@R10] *RANBP2* gene was deemed responsible for the progression of the mitotic spindle, and its suppression caused death in *BRAF*-like, but not in non-*BRAF*-like cell lines. These findings led to test the hypothesis of a potential susceptibility to mitotic spindle poisons of CRC models, and vinorelbine (VNR) was found the most active drug in *BRAF*-like models, showing no activity in *non-BRAF*-like ones. In a retrospective analysis of a previous study investigating vinca alkaloids in patients with mCRC, a *BRAF*-like gene signature was found in the only patient achieving a prolonged complete response. Drawing from such background, we carried out a phase II study aimed at investigating the activity of VNR in patients with BRAF V600E mutated mCRC.

Patients and methods {#s2}
====================

Study population {#s2a}
----------------

Patients with histologically confirmed mCRC harbouring BRAF V600E mutation were eligible if they had progressed during or within 3 months from the last administration of all standard treatment options (ie, fluoropyrimidines, irinotecan, oxaliplatin, bevacizumab, aflibercept, regorafenib, cetuximab or panitumumab) or were deemed not eligible for such therapies at investigator's judgement. Other inclusion criteria were age ≥18 years, Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0--1, at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumours (RECIST) V.1.1 and adequate hepatic, renal and bone marrow function. BRAF V600E mutation was detected either on primary tumours or metastatic lesions by Pyrosequencing or Sequenom Mass Array, as per local laboratory procedure. Mismatch Repair (MMR) status was evaluated by immunohistochemistry or multiplex PCR. The protocol was approved by local Ethics Committees at all participating institutions. All patients provided written informed consent before study entry.

Study design and statistical analysis {#s2b}
-------------------------------------

This was a multicentre, single-arm, phase 2 trial evaluating activity and safety of VNR in patients with BRAF V600E mutated mCRC. Enrolled patients received VNR orally at a dose of 60 mg/sqm or intravenously at a dose of 25 mg/sqm days 1 and 8 every 21 days. Treatment was continued until disease progression (PD), unacceptable toxicity, death or consent withdrawal.

The primary endpoint was objective response rate (ORR), defined as the proportion of patients that achieved a confirmed complete response or a partial response as best response according to RECIST V.1.1. Radiographic assessment of tumour response was carried out every 9 weeks. Secondary endpoints were progression-free survival (PFS), defined as the time from treatment start to the evidence of PD, or death due to any cause, whichever occurred first; overall survival (OS), defined as the time from treatment start to the date of death due to any cause and safety profile. The Kaplan-Meier method was used to estimate PFS and OS durations with 95% CI. Adverse events (AEs) were assessed according to the National Cancer Institute common toxicity criteria (V.4.0).

Considering the usual refractoriness of BRAF V600E mutated advanced mCRC to standard treatments, we assumed the hypothesis of achieving a 20% ORR with VNR monotherapy as acceptable for demonstrating a promising clinical activity.

Simon's optimal two-stage design[@R11] was adopted. The null hypothesis was set at 5% and tested against a one-sided alternative. According to the study design, in the first stage, n=21 patients would have been accrued. If two or more responses had been observed in the initial cohort, the study would have continued to the second step, and 20 additional patients would have been accrued for a total of 41. The null hypothesis would have been rejected in case of five or more responses. This design yielded a type I error rate of 0.05 (one sided) and a power of 90% for a true response rate of 20%.

Results {#s3}
=======

Study population {#s3a}
----------------

Between May 2016 and May 2017, a total of 20 patients were enrolled at four Italian centres. Baseline patients' and disease characteristics are summarised in [table 1](#T1){ref-type="table"}. The majority of patients were male (70%), aged \<70 years (85%), with ECOG PS 0 (55%). Primary tumours were more frequently located in right colon (65%). Mucinous histology was reported in 33% of cases and MMR deficiency was found in only 17% of cases. Ninety per cent of patients had more than one metastatic site at the time of enrolment and 75% had received at least two lines of systemic treatments. Previous regimens included fluoropyrimidines (90%), oxaliplatin (90%), irinotecan (80%), bevacizumab (75%), anti-Epidermal Growth Factor Receptor (EGFR)s (30%), regorafenib (30%) and TAS-102 (15%). Three patients had previously received BRAF targeted combinations, while one patient with a MMR-deficient tumour had been exposed to the immune checkpoint inhibitor nivolumab. Two patients had not received any treatment before VNR.

###### 

Patients' and tumours' characteristics

  Characteristics                                              n=20 N (%)
  ------------------------------------------------------------ -------------
  Sex                                                          
   Female                                                      6 (30)
   Male                                                        14 (70)
  Age                                                          
   Median (range)                                              64 (28--80)
   ≥70                                                         3 (15)
   \<70                                                        17 (85)
  Eastern Cooperative Oncology Group performance status        
   0                                                           11 (55)
   1                                                           9 (45)
  Primary tumour location                                      
   Right                                                       13 (65)
   Left                                                        5 (25)
   Extraperitoneal rectum                                      2 (10)
  Primary tumour resected                                      
   Yes                                                         18 (90)
   No                                                          2 (10)
  Grading                                                      
   G1--G2                                                      13 (65)
   G3--G4                                                      5 (25)
   Gx                                                          2 (10)
  Mucinous histology                                           
   Yes                                                         6 (33)
   No                                                          12 (67)
   NA                                                          2
  Microsatellite instability (MSI) status                      
   MSI-H                                                       3 (17)
   Microsatellite stability (MSS)/MSI-L                        15 (73)
   Not tested                                                  2
  Presentation of metastases                                   
   Synchronous                                                 12 (60)
   Metachronous                                                8 (40)
  Adjuvant chemotherapy                                        
   Fluoropyrimidine+oxaliplatin                                5 (25)
   Fluoropyrimidine                                            1 (5)
   No adjuvant                                                 14 (70)
  Number of previous lines of therapy for metastatic disease   
   0                                                           2 (10)
   1                                                           3 (15)
   2                                                           9 (45)
   ≥3                                                          6 (30)
  Number of metastatic sites                                   
   1                                                           2 (10)
   ≥2                                                          18 (90)
  Baseline Carcino-Embryonic Antigen                           
   Normal                                                      5 (29)
   \> Upper Limit of Normal (5 ng/mL)                          12 (71)
   Not available                                               3

Activity and efficacy {#s3b}
---------------------

No response was observed (ORR 0%). Stable disease was reported at the first CT scan reassessment in two (10%) patients and confirmed at the second assessment only in one case. Thus, the primary endpoint of the study was not met and the trial was stopped at the first step, not reaching the prespecified number of responses to move forward to the second step. At a median follow-up of 7.4 months, all patients experienced PD and 12 (60%) patients died. The median PFS was 1.0 month (95% CI 0.8 to 1.8) and the median OS was 2.1 months (95% CI 1.6 to 3.7) ([figure 1](#F1){ref-type="fig"}). Overall, six patients (30%) received poststudy therapy: regorafenib in four (20%) patients, chemotherapy rechallenge in one patient (5%), while one (5%) case with Methyl Guanine Methyl Transferase (*MGMT)* methylation responded to temozolomide.

![Kaplan-Meier curves of the probability of (A) progression-free survival (PFS) and (B) overall survival (OS).](esmoopen-2017-000241f01){#F1}

Safety {#s4}
======

All patients received at least one cycle of treatment and were assessed for safety. The median number of cycles administered per patient was 2 (range 1--9). Four (9%) out of 44 administered cycles were delayed because of toxicity. Only one patient required a dose reduction and another one early interruption due to toxicity. Treatment-related AEs are summarised in [table 2](#T2){ref-type="table"}. The most frequent grade ≥3 AE was neutropenia that occurred in three patients (15%) and became febrile in one case. No serious AEs or toxic deaths were reported.

###### 

Treatment-related adverse events according to NCI-CTCAE V.4.0

  ----------------------------------------------------------
  Adverse events          G1\      G2\      G3\      G4\
                          N (%)    N (%)    N (%)    N (%)
  ----------------------- -------- -------- -------- -------
  Nausea                  3 (15)   0        1 (5)    0

  Vomiting                1 (5)    0        1 (5)    0

  Diarrhoea               0        3 (15)   1 (5)    0

  Gastrointestinal pain   0        2 (10)   0        0

  Fatigue                 1 (5)    3 (15)   0        0

  Anaemia                 1 (5)    2 (10)   1 (5)    0

  Thrombocytopenia        0        0        0        0

  Neutropenia             0        1 (5)    3 (15)   1 (5)

  Febrile neutropenia     --       --       1 (5)    0
  ----------------------------------------------------------

Discussion {#s5}
==========

The identification of efficacious treatment options for patients bearing *BRAF*-mutated tumours is one of the most challenging unmet needs in the landscape of mCRC. While outcome results with conventional therapies are extremely poor and FOLFOXIRI plus bevacizumab is regarded by international guidelines as a preferred first-line choice for these patients,[@R12] targeted approaches recently provided encouraging but not outstanding results in pretreated patients. Considering the association of *BRAF* mutation with microsatellite instability, immunotherapy is emerging as a breakthrough option, but only in about one-third of patients.[@R13]

Based on the recent preclinical experience by Vecchione *et al*,[@R10] a robust and sound biological rationale supported the potential efficacy of VNR and thus encouraged the immediate translation of these findings in the clinical setting.

Unfortunately, results of our phase II study definitely failed to reveal even a minimal signal of activity in pretreated *BRAF*-mutated patients. Different explanations of this discrepancy can be hypothesised.

First, preclinical data suggested a potential activity of VNR in cancer cells bearing the BRAF-like signature and not in *BRAF-*mutated cells. However, although the concordance between *BRAF* mutation and *BRAF*-like signature is not absolute, this gene expression profile is found in more than 90% of *BRAF-*mutated tumours.[@R9] Thus, though acknowledging the limited size of our proof-of-concept trial, it seems rather unlike that none of our patients actually harboured the *BRAF*-like signature.

Second, no data are currently available with regard to the dynamic evolution of the *BRAF*-like signature across the time and under the pressure of multiple lines of treatment, so that the choice to mostly include pretreated patients might have affected our results.

Thirdly, *BRAF-*mutated tumours show a relevant molecular heterogeneity that might translate into clinical differences, both in terms of prognosis and sensitivity to different agents.[@R14]

In conclusion, based on our data, we believe that before moving to larger clinical trials investigating the potential role of VNR in *BRAF-*mutated or *BRAF*-like mCRC, a new step back to the bench should be taken in order to address these unanswered questions. For instance, the adoption of patient-derived xenografts as preclinical models might represent a good attempt to better mimic the human setting. Based on these findings, the *BRAF-*mutated population could be further dissected into different subgroups and a niche of benefit for VNR alone or in combination with other synthetically lethal agents could be found.
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